Related Experiment Video
Updated: Jun 6, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer
Simone E Dekker1,2, Lei Deng1,2
1Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Abstract:
KRAS mutation is one of the most common oncogenic drivers in non-small cell lung cancer. Since its discovery about four decades ago, drug development targeting KRAS has been met with countless failures. Recently, KRAS G12C, a subvariant of KRAS, became the first druggable KRAS mutation. The efficacy of the first-generation KRAS inhibitor is modest, but with scientific advancement, KRAS G12C inhibitors with higher potency are on the horizon. Additionally, novel therapeutic approaches targeting other KRAS subvariants are also being explored in clinical trials with encouraging early data. We will review the clinical advances and challenges for patients with KRAS-mutated non-small cell lung cancer, with a focus on small molecule inhibitors.
Insights
KRAS G12C mutations are now targetable in non-small cell lung cancer. New KRAS inhibitors show promise, offering hope for improved treatments beyond current modest efficacies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- KRAS mutations are key drivers in non-small cell lung cancer (NSCLC).
- Targeting KRAS has historically been challenging, marked by numerous drug development failures.
- KRAS G12C represents the first successfully targeted KRAS mutation.
Purpose of the Study:
- To review clinical progress in treating KRAS-mutated NSCLC.
- To discuss challenges and advancements in KRAS-targeted therapies.
- To focus on small molecule inhibitors for KRAS-mutated NSCLC.
Main Methods:
- Review of clinical trial data for KRAS inhibitors.
- Analysis of scientific literature on KRAS mutation and targeted therapy.
- Focus on small molecule inhibitor development and efficacy.
Main Results:
- The first-generation KRAS G12C inhibitors demonstrate modest efficacy.
- Next-generation KRAS G12C inhibitors with higher potency are under development.
- Emerging therapies targeting other KRAS subvariants show promising early clinical data.
Conclusions:
- Targeting KRAS G12C is a significant breakthrough in NSCLC treatment.
- Ongoing research is expanding therapeutic options for KRAS-mutated NSCLC.
- Small molecule inhibitors are central to advancing KRAS-targeted lung cancer therapy.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...